Company Description
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers.
The company’s lead drug candidate includes BNC210, a negative allosteric modulator of the α7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
The company has a collaboration with Merck & Co., Inc. to identify novel α7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder.
Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
Country | Australia |
Founded | 1996 |
IPO Date | Dec 16, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 24 |
CEO | Spyridon Papapetropoulos |
Contact Details
Address: 200 Greenhill Road Eastwood, SA 5063 Australia | |
Phone | 61 8 8150 7400 |
Website | bionomics.com.au |
Stock Details
Ticker Symbol | BNOX |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
IPO Price | $15.45 |
CIK Code | 0001191070 |
CUSIP Number | 09063M205 |
ISIN Number | US09063M2052 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Spyridon Papapetropoulos M.D., Ph.D. | Chief Executive Officer, President and Director |
Timothy M. Cunningham CPA, M.B.A. | Chief Financial Officer |
Elizabeth Doolin | Senior Vice President of Clinical Development |
Dr. Julie Kerner Ph.D. | Senior Vice President of Business Operations |
Dr. Mark A. Smith M.D., Ph.D. | Chief Medical Officer |
Adrian Hinton BEC, F.C.A. | Financial Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 10, 2024 | 8-K | Current Report |
Oct 9, 2024 | PRE 14A | Other preliminary proxy statements |
Oct 7, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Oct 2, 2024 | 8-K | Current Report |
Sep 30, 2024 | 10-K | Annual Report |
Jul 16, 2024 | 8-K | Current Report |
Jun 26, 2024 | EFFECT | Notice of Effectiveness |
Jun 26, 2024 | 424B3 | Prospectus |
Jun 21, 2024 | UPLOAD | Filing |
Jun 18, 2024 | F-1 | Registration statement for certain foreign private issuers |